Kiora Pharmaceuticals Financials
| KPRX Stock | USD 3.26 0.31 8.68% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.6 | 2.8997 |
|
|
The financial analysis of Kiora Pharmaceuticals is a critical element in measuring its lifeblood. Investors should not minimize Kiora Pharmaceuticals' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Net Income |
|
Kiora | Select Account or Indicator |
Understanding current and past Kiora Pharmaceuticals Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Kiora Pharmaceuticals' financial statements are interrelated, with each one affecting the others. For example, an increase in Kiora Pharmaceuticals' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Kiora Pharmaceuticals' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Kiora Pharmaceuticals. Check Kiora Pharmaceuticals' Beneish M Score to see the likelihood of Kiora Pharmaceuticals' management manipulating its earnings.
Kiora Pharmaceuticals Stock Summary
Kiora Pharmaceuticals competes with Tff Pharmaceuticals, Eliem Therapeutics, Inhibrx, and Enliven Therapeutics. Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Salt Lake City, Utah. Kiora Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US49721T3095 |
| CUSIP | 30233M107 30233M503 49721T309 49721T507 49721T101 |
| Location | Massachusetts; U.S.A |
| Business Address | 332 Encinitas Boulevard, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.kiorapharma.com |
| Phone | 858 224 9600 |
| Currency | USD - US Dollar |
Kiora Pharmaceuticals Key Financial Ratios
| Return On Equity | 0.14 | ||||
| Profit Margin | 0.20 % | ||||
| Operating Margin | (121.23) % | ||||
| Price To Sales | 0.67 X | ||||
| Gross Profit | (5.14 M) |
Kiora Pharmaceuticals Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 10.1M | 15.2M | 18.1M | 18.7M | 13.7M | 11.7M | |
| Other Current Liab | 1.1M | 1.3M | 1.2M | 2.1M | 1.3M | 1.3M | |
| Net Debt | (3.7M) | (823.6K) | (7.6M) | (5.9M) | (2.3M) | (2.5M) | |
| Retained Earnings | (100.2M) | (108.3M) | (124.7M) | (134.5M) | (147.0M) | (154.3M) | |
| Accounts Payable | 210.3K | 434.8K | 160.6K | 1.0M | 206.3K | 195.9K | |
| Cash | 3.8M | 1.2M | 7.9M | 6.0M | 2.5M | 4.7M | |
| Net Receivables | 4.9K | 91.0K | 529.6K | 1.4M | 2.0M | 2.2M | |
| Other Current Assets | 542.7K | 449.6K | 1.2M | 343.1K | 233.4K | 416.6K | |
| Total Liab | 3.5M | 8.2M | 8.8M | 7.3M | 7.6M | 12.5M | |
| Total Current Assets | 4.3M | 1.8M | 9.0M | 7.7M | 4.7M | 5.6M | |
| Short Term Debt | 83.9K | 260.6K | 237.7K | 211.6K | 94.1K | 89.4K | |
| Common Stock | 40.8K | 55.6K | 126.6K | 18.0K | 77.1K | 101.9K | |
| Intangible Assets | 4.1M | 9.7M | 8.7M | 10.7M | 8.8M | 7.9M | |
| Other Liab | 1.5M | 2.1M | 6.1M | 7.1M | 8.2M | 8.6M | |
| Net Tangible Assets | 7.2M | 4.9M | 3.3M | 9.1M | 10.4M | 10.9M | |
| Net Invested Capital | 6.6M | 7.3M | 9.2M | 11.4M | 6.1M | 7.5M | |
| Net Working Capital | 2.9M | 37.8K | 7.4M | 4.4M | 3.1M | 2.5M | |
| Capital Stock | 40.8K | 55.6K | 126.6K | 18.0K | 77.1K | 100.8K |
Kiora Pharmaceuticals Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Operating Income | (7.0M) | (8.2M) | (16.9M) | (12.3M) | (12.6M) | (13.2M) | |
| Ebit | (7.0M) | (6.8M) | (14.0M) | (13.7M) | (12.6M) | (13.2M) | |
| Research Development | 5.4M | 3.6M | 5.4M | 3.4M | 4.0M | 5.1M | |
| Ebitda | (6.8M) | (6.6M) | (13.7M) | (13.6M) | (12.4M) | (13.0M) | |
| Income Before Tax | (7.0M) | (8.1M) | (16.7M) | (13.7M) | (12.4M) | (13.0M) | |
| Net Income | (7.1M) | (8.1M) | (16.4M) | (13.6M) | (12.5M) | (13.1M) | |
| Income Tax Expense | 95.4K | 12.1K | (304.8K) | (113.0K) | 90.3K | 144.4K | |
| Interest Expense | 325.0 | 4.2K | 6.9K | 8.6K | 11.1K | 10.6K | |
| Gross Profit | 2.7M | (188.2K) | (227.3K) | (134.0K) | (4.0M) | (3.8M) | |
| Tax Provision | 95.4K | 12.1K | (304.8K) | (113.0K) | 90.3K | 94.8K | |
| Net Interest Income | 107.7K | 19.2K | (5.7K) | 48.3K | 167.4K | 175.8K | |
| Interest Income | 108.1K | 23.3K | 1.1K | 56.9K | 176.0K | 184.8K |
Kiora Pharmaceuticals Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Kiora Pharmaceuticals. It measures of how well Kiora is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Kiora Pharmaceuticals brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Kiora had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Kiora Pharmaceuticals has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (4.2M) | (2.6M) | 6.7M | (1.9M) | (3.6M) | (3.4M) | |
| Free Cash Flow | (8.2M) | (7.5M) | (11.0M) | (10.4M) | (9.6M) | (10.0M) | |
| Depreciation | 213.9K | 33.4K | 45.3K | 41.6K | 62.4K | 43.7K | |
| Other Non Cash Items | 500K | 326.7K | 6.0M | 2.1M | 3.9M | 4.1M | |
| Capital Expenditures | 270K | 20.1K | 133.8K | 63.9K | 1.0 | 0.95 | |
| Net Income | (7.1M) | (8.1M) | (16.4M) | (13.6M) | (12.5M) | (13.1M) | |
| End Period Cash Flow | 3.8M | 1.2M | 7.9M | 6.0M | 2.5M | 4.8M | |
| Net Borrowings | (9.8K) | (4.7K) | 278.2K | (212.3K) | (191.1K) | (181.5K) | |
| Change To Netincome | 961.3K | 1.4M | 895.8K | 6.3M | 7.3M | 7.6M |
Kiora Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Kiora Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Kiora Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Kiora Pharmaceuticals competition to find correlations between indicators driving Kiora Pharmaceuticals's intrinsic value. More Info.Kiora Pharmaceuticals is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers reporting about 0.95 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Kiora Pharmaceuticals is roughly 1.06 . At this time, Kiora Pharmaceuticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Kiora Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Kiora Pharmaceuticals Systematic Risk
Kiora Pharmaceuticals' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Kiora Pharmaceuticals volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Kiora Pharmaceuticals correlated with the market. If Beta is less than 0 Kiora Pharmaceuticals generally moves in the opposite direction as compared to the market. If Kiora Pharmaceuticals Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Kiora Pharmaceuticals is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Kiora Pharmaceuticals is generally in the same direction as the market. If Beta > 1 Kiora Pharmaceuticals moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Kiora Pharmaceuticals Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Kiora Pharmaceuticals' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Kiora Pharmaceuticals growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Kiora Pharmaceuticals December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Kiora Pharmaceuticals help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Kiora Pharmaceuticals. We use our internally-developed statistical techniques to arrive at the intrinsic value of Kiora Pharmaceuticals based on widely used predictive technical indicators. In general, we focus on analyzing Kiora Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Kiora Pharmaceuticals's daily price indicators and compare them against related drivers.
| Information Ratio | (0.08) | |||
| Maximum Drawdown | 16.59 | |||
| Value At Risk | (4.97) | |||
| Potential Upside | 5.95 |
Additional Tools for Kiora Stock Analysis
When running Kiora Pharmaceuticals' price analysis, check to measure Kiora Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kiora Pharmaceuticals is operating at the current time. Most of Kiora Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Kiora Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kiora Pharmaceuticals' price. Additionally, you may evaluate how the addition of Kiora Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.